世界の慢性閉塞性肺疾患（COPD）治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12165 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、慢性閉塞性肺疾患（COPD）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。慢性閉塞性肺疾患（COPD）治療の種類別市場規模（コルチコステロイド、ホスホジエステラーゼ4型阻害剤、気管支拡張剤、その他）、用途別市場規模（病院、クリニック、小売薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・慢性閉塞性肺疾患（COPD）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、Boehringer Ingelheim International GmbH、GlaxoSmithKline、Novartis AG、Teva Pharmaceutical Industries、Sunovion Pharmaceuticals、CHIESI Farmaceutici、Orion Corporation、​Mylan ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：コルチコステロイド、ホスホジエステラーゼ4型阻害剤、気管支拡張剤、その他 ・用途別分析2016年-2026年：病院、クリニック、小売薬局、その他 ・慢性閉塞性肺疾患（COPD）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・慢性閉塞性肺疾患（COPD）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・慢性閉塞性肺疾患（COPD）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・慢性閉塞性肺疾患（COPD）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・慢性閉塞性肺疾患（COPD）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Chronic Obstructive Pulmonary Disease (COPD) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Chronic Obstructive Pulmonary Disease (COPD) Treatment size is estimated to be USD 14740 million in 2026 from USD 13260 million in 2020, with a change XX% between 2020 and 2021. The global Chronic Obstructive Pulmonary Disease (COPD) Treatment market size is expected to grow at a CAGR of 2.7% for the next five years.

Market segmentation
Chronic Obstructive Pulmonary Disease (COPD) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Corticosteroids
Phosphodiesterase Type 4 Inhibitors
Bronchodilators
Others

Market segment by Application, can be divided into
Hospital
Clinic
Retail Pharmacies
Other

Market segment by players, this report covers
AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline
Novartis AG
Teva Pharmaceutical Industries
Sunovion Pharmaceuticals
CHIESI Farmaceutici
Orion Corporation
​Mylan

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Chronic Obstructive Pulmonary Disease (COPD) Treatment
1.2 Classification of Chronic Obstructive Pulmonary Disease (COPD) Treatment by Type
1.2.1 Overview: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Type in 2020
1.2.3 Corticosteroids
1.2.4 Phosphodiesterase Type 4 Inhibitors
1.2.5 Bronchodilators
1.2.6 Others
1.3 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Application
1.3.1 Overview: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Retail Pharmacies
1.3.5 Other
1.4 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size & Forecast
1.5 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Region
1.5.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region, (2016-2021)
1.5.3 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers
1.6.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints
1.6.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Boehringer Ingelheim International GmbH
2.2.1 Boehringer Ingelheim International GmbH Details
2.2.2 Boehringer Ingelheim International GmbH Major Business
2.2.3 Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.2.4 Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.3.4 GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.4.4 Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 Teva Pharmaceutical Industries
2.5.1 Teva Pharmaceutical Industries Details
2.5.2 Teva Pharmaceutical Industries Major Business
2.5.3 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.5.4 Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
2.6 Sunovion Pharmaceuticals
2.6.1 Sunovion Pharmaceuticals Details
2.6.2 Sunovion Pharmaceuticals Major Business
2.6.3 Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.6.4 Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Sunovion Pharmaceuticals Recent Developments and Future Plans
2.7 CHIESI Farmaceutici
2.7.1 CHIESI Farmaceutici Details
2.7.2 CHIESI Farmaceutici Major Business
2.7.3 CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.7.4 CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 CHIESI Farmaceutici Recent Developments and Future Plans
2.8 Orion Corporation
2.8.1 Orion Corporation Details
2.8.2 Orion Corporation Major Business
2.8.3 Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.8.4 Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Orion Corporation Recent Developments and Future Plans
2.9 ​Mylan
2.9.1 ​Mylan Details
2.9.2 ​Mylan Major Business
2.9.3 ​Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
2.9.4 ​Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 ​Mylan Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Market Share
3.2.2 Top 10 Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Application (2016-2021)
5.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2026)
6.2 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2026)
6.3 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
6.3.1 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2026)
6.3.2 United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2026)
7.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2026)
7.3 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
7.3.1 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2026)
7.3.2 Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
7.3.3 France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Region
8.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Region (2016-2026)
8.3.2 China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
8.3.5 India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2026)
9.2 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2026)
9.3 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
9.3.1 South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size by Country
10.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 9. AstraZeneca Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Boehringer Ingelheim International GmbH Corporate Information, Head Office, and Major Competitors
Table 11. Boehringer Ingelheim International GmbH Major Business
Table 12. Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 13. Boehringer Ingelheim International GmbH Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 15. GlaxoSmithKline Major Business
Table 16. GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 17. GlaxoSmithKline Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 21. Novartis AG Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors
Table 23. Teva Pharmaceutical Industries Major Business
Table 24. Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 25. Teva Pharmaceutical Industries Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Sunovion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Sunovion Pharmaceuticals Major Business
Table 28. Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 29. Sunovion Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. CHIESI Farmaceutici Corporate Information, Head Office, and Major Competitors
Table 31. CHIESI Farmaceutici Major Business
Table 32. CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 33. CHIESI Farmaceutici Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Orion Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Orion Corporation Major Business
Table 36. Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 37. Orion Corporation Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. ​Mylan Corporate Information, Head Office, and Major Competitors
Table 39. ​Mylan Major Business
Table 40. ​Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Product and Solutions
Table 41. ​Mylan Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) by Players (2019-2021)
Table 43. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Players (2019-2021)
Table 44. Breakdown of Chronic Obstructive Pulmonary Disease (COPD) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Chronic Obstructive Pulmonary Disease (COPD) Treatment Players Head Office, Products and Services Provided
Table 46. Chronic Obstructive Pulmonary Disease (COPD) Treatment Mergers & Acquisitions in the Past Five Years
Table 47. Chronic Obstructive Pulmonary Disease (COPD) Treatment New Entrants and Expansion Plans
Table 48. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) by Type (2016-2021)
Table 49. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Type (2016-2021)
Table 50. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Forecast by Type (2021-2026)
Table 51. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2021)
Table 52. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Forecast by Application (2021-2026)
Table 53. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Picture
Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Type in 2020
Figure 3. Corticosteroids
Figure 4. Phosphodiesterase Type 4 Inhibitors
Figure 5. Bronchodilators
Figure 6. Others
Figure 7. Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Application in 2020
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Other Picture
Figure 12. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region in 2020
Figure 16. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers
Figure 22. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints
Figure 23. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends
Figure 24. AstraZeneca Recent Developments and Future Plans
Figure 25. Boehringer Ingelheim International GmbH Recent Developments and Future Plans
Figure 26. GlaxoSmithKline Recent Developments and Future Plans
Figure 27. Novartis AG Recent Developments and Future Plans
Figure 28. Teva Pharmaceutical Industries Recent Developments and Future Plans
Figure 29. Sunovion Pharmaceuticals Recent Developments and Future Plans
Figure 30. CHIESI Farmaceutici Recent Developments and Future Plans
Figure 31. Orion Corporation Recent Developments and Future Plans
Figure 32. ​Mylan Recent Developments and Future Plans
Figure 33. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Players in 2020
Figure 34. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share in 2020
Figure 36. Global Top 10 Players Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Type in 2020
Figure 39. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share Forecast by Type (2021-2026)
Figure 40. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Share by Application in 2020
Figure 41. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share Forecast by Application (2021-2026)
Figure 42. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2016-2026)
Figure 43. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2016-2026)
Figure 44. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2016-2026)
Figure 45. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2016-2026)
Figure 49. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2016-2026)
Figure 50. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2016-2026)
Figure 51. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Region (2016-2026)
Figure 59. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2016-2026)
Figure 66. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2016-2026)
Figure 67. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source

---